BRAIN Biotech AG (ETR:BNN)

Germany · Delayed Price · Currency is EUR

2.710

-0.210 (-7.19%)

Jul 6, 2026, 1:22 PM CET

42.26% (1Y)

Market Cap	63.79M +56.6%
Revenue (ttm)	48.31M -9.7%
Net Income	-11.02M
EPS	-0.51
Shares Out	21.85M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,571
Open	2.750
Previous Close	2.920
Day's Range	2.710 - 2.800
52-Week Range	1.850 - 3.890
Beta	0.63
Analysts	Strong Buy
Price Target	5.50 (+102.95%)
Earnings Date	Aug 27, 2026

About BRAIN Biotech AG

BRAIN Biotech AG provides bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two segments: BRAINBiocatalysts and BRAINBioIncubator. The BRAINBiocatalysts segment develops, produces, and distributes specialty enzymes, microorganisms, and ingredients. The BRAINBioIncubator segment encompasses a pipeline of research-intensive development projects primarily for the life sciences industry. The company offers enzymes, biocatalysts, microorganisms, and other bio... [Read more]

Industry Specialty Chemicals

Sector Materials

Founded 1993

Employees 280

Stock Exchange Deutsche Börse Xetra

Ticker Symbol BNN

Full Company Profile

Financial Performance

In fiscal year 2025, BRAIN Biotech AG's revenue was 50.22 million, a decrease of -9.52% compared to the previous year's 55.50 million. Losses were -11.74 million, 5.53% more than in 2024.

Financial Statements

Analyst Summary

According to 4 analysts, the average rating for BNN stock is "Strong Buy." The 12-month stock price target is €5.50, which is an increase of 102.95% from the latest price.

Price Target

€5.50

(102.95% upside)

Analyst Consensus: Strong Buy

Stock Forecasts